HIBCH and metabolic dysfunction-associated steatotic liver disease: Exploring HIBCH as a therapeutic target is further motivated by the markedly increased extracellular MMA concentrations we observed upon HIBCH overexpression, as MMA (an established marker of vitamin B12 status) has been identified as a marker of advanced liver fibrosis in patients with NAFLD.61